Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
- About
Tvardi Therapeutics, Inc. (TVRD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/18/2025: TVRD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Highly popular stock, broad analyst coverage, trusted insights, strong investor interest.
1 Year Target Price $
1 Year Target Price $
| 4 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -33.72% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/18/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 8.14 - 34.31 | Updated Date 05/15/2025 |
52 Weeks Range 8.14 - 34.31 | Updated Date 05/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating 5 | Target Price - | Buy - | Strong Buy 4 |
Buy - | Strong Buy 4 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Tvardi Therapeutics, Inc.
Company Overview
History and Background
Tvardi Therapeutics, Inc. is a privately held clinical-stage biopharmaceutical company focused on developing STAT3 inhibitors for the treatment of cancer and fibrosis. Founded in 2017, Tvardi is rapidly advancing its lead small molecule STAT3 inhibitor through clinical trials.
Core Business Areas
- Drug Development: Development of small molecule inhibitors targeting STAT3 for various cancer and fibrotic indications.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of its drug candidates.
- Research and Discovery: Discovery and pre-clinical development of novel therapies.
Leadership and Structure
The leadership team consists of experienced executives in drug development and biotechnology. The organizational structure is typical of a biotech company, focusing on research, development, and clinical operations.
Top Products and Market Share
Key Offerings
- Tvardi's STAT3 Inhibitor (TBD): A novel small molecule STAT3 inhibitor in clinical development for various cancers and fibrotic diseases. Market share is currently 0% as the product is still in clinical trials. Competitors include companies developing alternative STAT3 inhibitors or therapies for the same indications, such as various big pharma companies targeting similar pathways.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, long development timelines, and stringent regulatory requirements. There is increasing demand for novel cancer and fibrosis treatments.
Positioning
Tvardi is positioning itself as a leader in STAT3 inhibition for cancer and fibrosis, targeting unmet medical needs. Its competitive advantage lies in its novel small molecule inhibitor and focused approach.
Total Addressable Market (TAM)
The total addressable market for cancer and fibrosis therapies is estimated to be billions of dollars. Tvardi is positioned to capture a portion of this TAM with its innovative approach.
Upturn SWOT Analysis
Strengths
- Novel STAT3 inhibitor
- Strong management team
- Focused therapeutic area
- Positive preclinical data
Weaknesses
- Limited financial resources (private company)
- Early stage clinical development
- High risk of clinical trial failure
- Dependence on key personnel
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Positive clinical trial results
- FDA approval of STAT3 inhibitor
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- There are no direct publicly traded competitors focusing solely on STAT3 inhibition. Many big pharma companies (Pfizer (PFE), Novartis (NVS), Roche (ROG)) are pursuing treatments for related indications.
Competitive Landscape
The competitive landscape is characterized by established pharmaceutical companies with significant resources. Tvardi's advantage lies in its specific focus on STAT3 inhibition, but it faces challenges in terms of resources and market access.
Growth Trajectory and Initiatives
Historical Growth: Growth is characterized by advancing its lead compound through preclinical and clinical development.
Future Projections: Future growth depends on clinical trial success, regulatory approvals, and potential partnerships.
Recent Initiatives: Focus on advancing clinical trials of their STAT3 inhibitor in multiple cancer types.
Summary
Tvardi Therapeutics is a privately held biotech company with a promising STAT3 inhibitor in clinical development. Its success hinges on clinical trial outcomes and potential partnerships. The company faces the typical challenges of early-stage biotech companies, including limited resources and high risk of clinical trial failure, but its novel approach positions it well for future growth if it can overcome these challenges.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Industry Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is based on publicly available information and is not financial advice. The information provided is for informational purposes only and should not be construed as investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tvardi Therapeutics, Inc.
Exchange NASDAQ | Headquaters Sugar Land, TX, United States | ||
IPO Launch date 2014-01-31 | CEO & Director Dr. Imran Alibhai Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://tvarditherapeutics.com |
Full time employees - | Website https://tvarditherapeutics.com | ||
Tvardi Therapeutics, Inc. operates as a biotechnology company that develops medicines for cancer, chronic inflammation diseases, and fibrosis diseases. It develops inhibitors of STAT3, a molecule implicated in the initiation and progression of cancer and fibrosis. Its pipeline includes TTI-101, a small-molecule inhibitor of signal transducers and activators of transcription; and TTI-109, a STAT3 inhibitor for clinical use, including tolerability, bioavailability, and potency. Tvardi Therapeutics, Inc. was incorporated in 2017 and is based in Sugar Land, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.